Monday, 17 August 2026European Markets
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
AI Platforms Move to Shore Up Trust as Leadership Shifts and AI-Adjacent Markets Wobble
Major AI and media platforms are converging on trust and accountability measures — Anthropic's Claude adding watermarks, Spotify labeling AI artists — just as OpenAI loses special-projects lead Brad Lightcap and Meta's Zuckerberg publishes a defensive manifesto on AI's societal role. In parallel, AI-adjacent financial dynamics are surfacing real stress: Wall Street firms are paying for privileged early access to Trump's Truth Social posts for trading edge, while Trump Media itself reports a $238M loss driven by falling crypto holdings, highlighting how information asymmetry and speculative digital assets are becoming entangled with AI-era platforms.
Our read on the data ›
Signals we're tracking
Satellite-Terrestrial Network Integration Acceleration
Increased investment and launches in hybrid satellite-cellular networks across telecom industry; competitive responses from other carriers; regulatory activity around satellite spectrum; expansion of emergency/rural connectivity use cases
Patterns we're watching ›
Where sources disagree
JPMorgan Chase & Co.
Both facts report JPMorgan Chase & Co.'s revenue for the same fiscal period (FY 2025) with the same observation date (2025-12-31), but with different values: $182.447 billion vs. $185 billion. The ~1.4% difference ($2.553 billion) is too large to be explained by rounding alone and represents conflicting data for the identical time period.
We flag conflicts openly ›
Recently verified
Checked against the original source
4,809
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,809 facts checked against source5,205 source documents archived
Work with this data → vianewsagency.com

HOFSETH BIOCARE Stock Over 22% Up In The Last 10 Sessions

Loading stream...

(VIANEWS) - Shares of HOFSETH BIOCARE (Oslo Børs Benchmark Index_GI: HBC.OL) rose by a staggering 22.4% in 10 sessions from kr2.5 to kr3.06 at 13:38 EST on Thursday, following the last session's upward trend. Oslo Børs Benchmark Index_GI is jumping 0.54% to kr1,249.22, after two consecutive sessions in a row of gains.

HOFSETH BIOCARE's last close was kr2.88, 46.86% below its 52-week high of kr5.42.

About HOFSETH BIOCARE

Hofseth BioCare ASA operates as a consumer and pet health ingredient supplier in Norway and internationally. Its products include Brilliant salmon oil; OmeGo salmon oil for supporting healthy cholesterol and cardiovascular function; ProGo, a salmon protein hydrolysate powder for treatment of irondeficiency anaemia, irritable bowel syndrome (IBS) and sarcopenia; CalGo, a marine calcium powder produced to support cartilage function, joint health, and bone strength; CollaGo, an hair, skin, and nails health treatment and antioxidant; and PetGo, a non-soluble protein. The company distributes its products through distributors, agents, and its own sales force. Hofseth BioCare ASA was founded in 2000 and is headquartered in Ålesund, Norway.

Earnings Per Share

As for profitability, HOFSETH BIOCARE has a trailing twelve months EPS of kr-0.31.

The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is negative -94.78%.

Volume

Today's last reported volume for HOFSETH BIOCARE is 184259 which is 31.16% below its average volume of 127327.

Moving Average

HOFSETH BIOCARE's value is higher than its 50-day moving average of kr2.89 and below its 200-day moving average of kr3.27.

More news about HOFSETH BIOCARE (HBC.OL).